The company anticipates five new product approvals in 2025 ... sales target to over £40 billion. Overall GSK ranks 5th on our list of the cheap pharmaceutical stocks to buy according to analysts.

It offers pharmaceutical products in the areas of gastroenterology ... It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with ...

The company reported strong performance across key product portfolios ... In the vaccines segment, GlaxoSmithKline Pharmaceuticals maintained leadership in the self-pay private market for ...

Discover GSK's impressive stock surge, boosted by strong earnings, a share buyback program, and a focus on specialty medicines.

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other ...